MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Naloxone

Selected References

  • Blandthorn J, et al. 2018. Managing opioid overdose in pregnancy with take-home naloxone. Aust N Z J Obstet Gyneacol 58(4):460-62.
  • Debelak K, et al. 2013. Buprenorphine + Naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict; 22(3):252-54.
  • Flannagan KS, et al. 2020. Prescription opioid use among populations of reproductive age: effects on fertility, pregnancy loss, and pregnancy complications. Epidemiologic reviews. 42(1): 117-33.
  • Gawronski KM, et al. 2014. Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone. 2:2050312114530282.
  • Goshgarian G, et al. Prenatal Buprenorphine/Naloxone or Methadone Use on Neonatal Outcomes in Michigan. Cureus.14(8).
  • Griffiths S, et al. 2021. Use of injectable opioid agonist therapy in a in-patient setting for a pregnant patient with opioid use disorder: A case report. Journal of Addiction Medicine. 15(5): 435-38.
  • Jones HE & Kraft WK. 2019. Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. Clin Perinatol; 46(2):349-366.
  • Jansson LM, et al. 2024. Buprenorphine-Naloxone Maintenance and Lactation. Journal of Human Lactation 40(1): 113-19.
  • Jumah NA, et al. 2016. Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population. BMJ Open; 6(10):e011774.
  • Kanervo M, et al. 2023. Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder. Acta Obstetricia et Gynecologica Scandinavica. 102(3): 313-22.
  • Kanervo M, et al. 2024. Intrauterine exposure to maternal opioid maintenance treatment and associated risk factors may impair child growth. Acta Paediatrica.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.